Should I buy or sell LianBio stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LianBio in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LIAN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIAN, but not buy additional shares or sell existing shares. View LIAN analyst ratings or view top-rated stocks .

What is LianBio's stock price target for 2024?

3 brokers have issued 1 year price objectives for LianBio's shares. Their LIAN share price targets range from $3.00 to $9.00. On average, they predict the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 1,739.1% from the stock's current price. View analysts price targets for LIAN or view top-rated stocks among Wall Street analysts .

How have LIAN shares performed in 2024?

LianBio's stock was trading at $4.47 at the beginning of 2024. Since then, LIAN shares have decreased by 93.5% and is now trading at $0.29. View the best growth stocks for 2024 here .

How were LianBio's earnings last quarter?

LianBio (NASDAQ:LIAN) posted its earnings results on Monday, March, 27th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.10.

How often does LianBio pay dividends? What is the dividend yield for LianBio?

LianBio declared a -- dividend on Tuesday, February 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $4.80 per share on Thursday, March 14th. The ex-dividend date is Friday, March 15th. Read our dividend analysis for LIAN .

What ETF holds LianBio's stock?

Loncar China Biopharma ETF holds 27,778 shares of LIAN stock, representing 1.31% of its portfolio.

When did LianBio IPO?

LianBio (LIAN) raised $325 million in an initial public offering (IPO) on the week of November 1st 2021. The company issued 20,300,000 shares at $16.00 per share. Goldman Sachs, Jefferies and BofA Securities served as the underwriters for the IPO.

How do I buy shares of LianBio?

Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LIAN

LianBio (LIAN) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free LIAN Stock Alerts

$0.29

-0.01 (-3.33%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.28
▼
$0.30
50-Day Range: $0.29
▼
$4.99
52-Week Range: $0.27
▼
$4.99

Volume: 126,900 shs
Average Volume: 1.04 million shs
Market Capitalization: $31.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.33

Get LianBio alerts:

LianBio MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 1,739.1% Upside
$5.33 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From $2.40 to ($0.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.65 out of 5 stars

Medical Sector

856th out of 918 stocks

Biotechnology Industry

35th out of 43 stocks

3.0

Analyst's Opinion

Consensus Rating
LianBio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.
Amount of Analyst Coverage
LianBio has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for LIAN.

0.0

Dividend Strength

Dividend Yield
LianBio does not currently pay a dividend.
Dividend Growth
LianBio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LIAN.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for LianBio this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, LianBio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.59% of the stock of LianBio is held by insiders.
Percentage Held by Institutions
74.85% of the stock of LianBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for LianBio are expected to decrease in the coming year, from $2.40 to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of LianBio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of LianBio is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
LianBio has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About LianBio Stock (NASDAQ:LIAN)

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

LIAN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LIAN Stock News Headlines

April 13, 2024 | americanbankingnews.com

LianBio (NASDAQ:LIAN) Trading Down 5.3%

March 15, 2024 | investorplace.com

Why Is LianBio (LIAN) Stock Moving Today?

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

February 28, 2024 | globenewswire.com

LianBio Announces Voluntarily Delisting from Nasdaq

February 23, 2024 | seekingalpha.com

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

February 13, 2024 | markets.businessinsider.com

LianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-Market

February 13, 2024 | marketwatch.com

LianBio to Wind Down Operations, Declares Special Dividend

February 13, 2024 | marketwatch.com

LianBio Shares Gain After Co Announces Plans to Wind Down

April 18, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 13, 2024 | finance.yahoo.com

LianBio Announces Completion of Strategic Review

January 3, 2024 | markets.businessinsider.com

B of A Securities Downgrades LianBio: Here's What You Need To Know

December 26, 2023 | markets.businessinsider.com

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

December 26, 2023 | finance.yahoo.com

LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets

December 20, 2023 | realmoney.thestreet.com

Interest Is Growing for Smaller, More Speculative Names

December 20, 2023 | finance.yahoo.com

LianBio Announces Departure of Chief Financial Officer

December 19, 2023 | marketwatch.com

LianBio Names Stone as Interim CEO as Wang Resigns

December 19, 2023 | finance.yahoo.com

LianBio Announces Departure of Chief Executive Officer

December 6, 2023 | finance.yahoo.com

LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences

December 1, 2023 | finance.yahoo.com

LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

November 14, 2023 | finance.yahoo.com

LianBio (LIAN) Reports Q3 2023 Financial Results: Strategic Review in Progress Amid Clinical ...

November 13, 2023 | finance.yahoo.com

LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023 | finance.yahoo.com

All You Need to Know About LianBio Sponsored ADR (LIAN) Rating Upgrade to Strong Buy

October 30, 2023 | finance.yahoo.com

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

October 27, 2023 | fool.com

Why LianBio Stock Is Shooting Through the Roof This Week

October 25, 2023 | finance.yahoo.com

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

October 25, 2023 | markets.businessinsider.com

Raymond James Maintains Outperform Rating for LianBio: Here's What You Need To Know

October 24, 2023 | markets.businessinsider.com

LianBio Reaches Agreement With Bristol Myers Squibb For Mavacamten; Stock Up

See More Headlines

Receive LIAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LianBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/27/2023
Dividend Payable: 3/14/2024
Ex-Dividend for 3/14 Dividend: 3/15/2024
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:LIAN
CUSIP: N/A
CIK: 1831283
Web: www.lianbio.com
Phone: 609-486-2308
Fax: N/A
Employees: 163
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.33
High Stock Price Target: $9.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +1,739.1%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 0.12
P/E Growth: N/A
Net Income: $-110,290,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -33.17%
Return on Assets: -30.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.06
Quick Ratio: 10.06

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.71 per share
Price / Book: 0.11

Miscellaneous

Outstanding Shares: 108,063,000
Free Float: 99,861,000
Market Cap: $31.34 million
Optionable: Not Optionable
Beta: 0.23

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Konstantin Poukalov (Age 40)
Founder & Executive Chairman
Mr. Adam Leo Stone (Age 43)
Interim CEO & Director
Ms. Ehong Gu
Interim CFO, VP & Head of Global Finance
Ji Chen
Senior VP & General Counsel
Ms. Brianne Jahn (Age 38)
Chief Business Officer
Comp: $697.47k
Dr. Michael Humphries M.D.
Chief Scientific Advisor
Mr. Levvy Lv D. Eng
Senior VP & Global Head of Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LIAN Stock Analysis - Frequently Asked Questions

Should I buy or sell LianBio stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LianBio in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" LIAN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LIAN, but not buy additional shares or sell existing shares.
View LIAN analyst ratings or view top-rated stocks.
What is LianBio's stock price target for 2024?: 3 brokers have issued 1 year price objectives for LianBio's shares. Their LIAN share price targets range from $3.00 to $9.00. On average, they predict the company's share price to reach $5.33 in the next twelve months. This suggests a possible upside of 1,739.1% from the stock's current price.
View analysts price targets for LIAN or view top-rated stocks among Wall Street analysts.
How have LIAN shares performed in 2024?: LianBio's stock was trading at $4.47 at the beginning of 2024. Since then, LIAN shares have decreased by 93.5% and is now trading at $0.29.
View the best growth stocks for 2024 here.
How were LianBio's earnings last quarter?: LianBio (NASDAQ:LIAN) posted its earnings results on Monday, March, 27th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.10.

How often does LianBio pay dividends? What is the dividend yield for LianBio?: LianBio declared a -- dividend on Tuesday, February 13th. Stockholders of record on Tuesday, February 27th will be given a dividend of $4.80 per share on Thursday, March 14th. The ex-dividend date is Friday, March 15th.
Read our dividend analysis for LIAN.
What ETF holds LianBio's stock?: Loncar China Biopharma ETF holds 27,778 shares of LIAN stock, representing 1.31% of its portfolio.
When did LianBio IPO?: LianBio (LIAN) raised $325 million in an initial public offering (IPO) on the week of November 1st 2021. The company issued 20,300,000 shares at $16.00 per share. Goldman Sachs, Jefferies and BofA Securities served as the underwriters for the IPO.
How do I buy shares of LianBio?: Shares of LIAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIAN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

LianBio (LIAN) Stock Price, News & Analysis

LianBio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About LianBio Stock (NASDAQ:LIAN)

LIAN Stock Price History

LIAN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

LIAN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™